799.20
-0.06%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Granules India
Its shares trade on NSE under the ticker GRANULES.NS. It has been listed since 20 September 1995. In the fiscal year to 31 March 2025, it reported revenue of ₹44.82bn and net income of ₹5.02bn. At that date it held total assets of ₹62.53bn and shareholders' equity of ₹37.16bn.
Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The firm operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The firm has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The firm sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Sept 1995
- Employees
- 3,686
- Website
- granulesindia.com ↗
Leadership
Pay as last reported
- Dr. Krishna ChigurupatiExecutive Chairman of the Board, Managing Director, since 2014₹316.4m
- Dr. Kandiraju RaoChief Executive Officer, Joint Managing Director, Executive Director, since 2022₹96.5m
- Mr. Mukesh SuranaChief Financial Officer
- Mr. Sanjay KumarPresident and Chief Strategy and Sustainability Officer, since 2024
- Mr. Ramraj RangarajuluPresident and Head - Formulations Operations
- Mr. Atul DhavleChief Human Resource Officer
- Dr. Rajesh KapoorSenior Vice President, Global Head of Quality
- Mr. G. N. PrashanthSenior Vice President & Head Corporate Quality
- Mr. Manikandan RamalingamSenior Vice President & Head Formulation R&D
- Dr. P. V. SrinivasChief Technology Officer - Head of R&D
- Ms. Chaitanya TummalaCompliance Officer, Company Secretary₹7.9m
- Ms. Priyanka ChigurupatExecutive Director, Executive Director of Granules Pharmaceuticals, Inc. & Granules USA, Inc., since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 70
- Social
- 61
- Governance
- 62
- Direct emissions (scope 1)
- 56,254 t
- Energy emissions (scope 2)
- 31,632 t
- Women in the workforce
- 7.78901%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Granules India Ltd has a strong presence in the pharmaceutical industry.
- The company has a diverse portfolio of products.
- Granules India Ltd has established strong relationships with clients, suppliers, and distributors.
Weaknesses
- The company may face challenges in maintaining consistent quality across its product range.
- Granules India Ltd relies heavily on third-party suppliers for raw materials, which poses a risk to its supply chain.
Opportunities
- The growing demand for generic drugs presents a significant opportunity for Granules India Ltd to expand its market share.
- Expansion into new geographic markets can help the company diversify its revenue streams.
- Increasing investments in research and development can enable Granules India Ltd to develop innovative products.
Threats
- Intense competition within the pharmaceutical industry may impact Granules India Ltd's market position.
- Changes in government regulations and policies can pose a threat to the company's operations.
- Economic downturns or fluctuations in currency exchange rates can affect Granules India Ltd's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.